INTRODUCTION
Dyspepsia, defined by an International Working Group as "persistent or recurrent abdominal pain or abdominal discomfort (a subjective, negative feeling) centered in (mainly localized to) the upper abdomen" [1] , is very common in the developed and the developing world. Approximately one in four adults in the United States and Australia and 40 percent in the United Kingdom suffer from various dyspeptic symptoms [2] [3] [4] . The prevalence is higher in some developing countries [5, 6] . However, among the majority of patients, no evidence of organic disease will be found [7] , and a diagnosis of non-ulcer dyspepsia (NUD)b will be made in these patients [8] .
Helicobacterpylori infection also is very common in the general populations of western countries. Epidemiological studies have shown that about 30 to 60 percent of NUD patients are infected with H. pylori [9-1 1] . However, the results in the literature regarding a causal association between H. pylori infection and NUD are conflicting [12] . Moreover, whether treatment to eradicate the infection is beneficial to the improvement of dyspeptic symptoms remains inconclusive. Many clinical trials suffer from methodological problems making interpretation difficult [13] . This article aims to discuss whether H. pylori infection may have any causal link to the development of symptoms [14] [15] [16] , whereas others show the infection to be more common in asymptomatic controls [17, 18] . Unfortunately, many studies suffer from serious flaws in study design including the representativeness of the control group to the general population to which the dyspeptic patients belonged. Most studies have not used race, age-and sex-matched controls [12, 13] , which are strongly related to the prevalence of H. pylori infection in the general population [19, 20] . This also is the case in dyspeptic patients in which the prevalence of H. pylori infection increases with advancing age [18, 21] . A recent review combined 19 epidemiological studies published between 1987 and 1994 and found a relative risk of 2.3 (95 percent confidence intervals 1.9-2.7) for a link between H. pylori infection and NUD irrespective of study quality [22] .
An interesting study from Italy has shown a positive relation between H. pylori seroprevalence and the frequency of dyspeptic symptoms [23] . In [23] . Another prospective study also found that subjects who became infected with H. pylori were four times more likely to have upper gastrointestinal symptoms than H. pylori-negative controls although the sample size was small [24] .
Dyspeptic symptoms have been divided into three general subgroups based on which symptoms are predominant: namely, ulcer-like, reflux-like and dysmotility-like symptoms. It has been suggested that H. pylori infection may be more commonly associated with ulcer-like dyspepsia than with dysmotility-like symptoms [15, 25] . However, most studies have failed to demonstrate any association between individual symptoms and H. pylori status [12, 26] [22, [27] [28] [29] . It is likely that a constellation of factors leads to the development of the symptom complex of dyspepsia ( Figure 1) .
Could H. pylori infection be considered the trigger for the development of dyspepsia? There is evidence to show that a substantial proportion of NUD patients with H. pylori infection have abnormalities of gastric acid secretion similar to duodenal ulcer patients [27] . In a well-designed study, El-Omar et al. compared 25 H. pylori-infected NUD patients with 25 H. pylori-positive asymptomatic subjects, 25 H. pylori-negative healthy controls and 25 H. pylori-infected duodenal ulcer patients. They found that gastrin-releasing peptide-stimulated gastric acid secretion in the infected NUD patients was 1.5 times that of the H. pylori-positive asymptomatic controls and five times that of the H. pylorinegative healthy controls, although the median acid output was lower than that of H. pylori infected duodenal ulcer patients [27] . However, since this study did not include H. pylori-negative NUD patients, the generalizability of the results needs to be confirmed. Furthermore, it is not known whether eradication of H. pylori infection will restore the abnormal response of acid secretion to GRP stimulation, although this would be anticipated from the results in duodenal ulcer patients [30] .
Dyspeptic patients have a spectrum of motor disturbances including an increased gastric perception to distension, antral hypomotility and delayed gastric emptying [31] [32] [33] . However, results regarding the relation of H. pylori infection to the altered gastric motility in NUD patients have been conflicting. Some studies suggested that H. pylori infection is associated with delayed [34, 35] or accelerated gastric emptying [36] ; however, the majority of studies have not shown any association between the H. pylori status of NUD patients and gastric motility [37] [38] [39] [40] . This may be due to mild gastric mucosal inflammation with less dense H. pylori infection in dyspeptic patients, since there is some evidence to suggest that the degree of mucosal inflammation is associated with the number of bacteria [41] , and sensory abnormalities have been linked to a subgroup of patients with high anti-H. pylori titers [33] . H. pylori-induced mucosal inflammation and the subsequent release of chemokines and cytokines may excite neurons and increase pain sensation through the release of mucosal prostaglandin E2 as has been shown in a rabbit ear pain model [42] . IL-Ii increases enteric neural sensitivity and stimulates IL-1, IL-6 and TNFa secretion by intestinal smooth muscle cells (for review see [22] [44] .
RESULTS OF CLINICAL TRIALS
The NIH Consensus Conference in 1994 did not recommend eradication treatment for dyspeptic patients infected with H. pylori [45] . Indeed, the results of studies in the literature are conflicting regarding improvement in dyspeptic symptoms after treatment for H. pylori infection in dyspeptic patients. As critically reviewed by Talley and van Zanten [ 13, 46] , previous studies have many methodological problems and provide data of variable quality, and it is difficult to draw a firm conclusion. A recent meta-analysis combining results from 10 studies, though open to criticism, showed that H. pylori eradication treatment improved dyspeptic symptoms [47] . Symptom improvement was more evident after a mean follow-up of longer than 12 months [47] . This is in agreement with the histological changes seen in patients after successful treatment of the infection [48] . These results suggest that a subgroup of dyspeptic patients might benefit from eradication treatment over a longer time period than has been observed in most studies to date.
Numerous clinical trials with different drug combinations have been undertaken in an attempt to relieve symptoms in dyspeptic patients. In studies that compared the effect of different bismuth salts with placebo on the improvement of dyspeptic symptoms, poor study quality and the difficulty of blinding studies in patients treated with bismuth have made the results difficult to interpret [13] . In a well-designed, placebo-controlled trial, Marshall et al. compared the effect of bismuth subsalicylate (BSS) 512 mg qid and placebo given for 3 weeks after a two-week placebo run-in period in 50 H. pylori-infected NUD patients [49] . They found that 70 percent of the infection was cleared in the BSS treatment group, and the histological improvement in gastritis paralleled H. pylori suppression. Lower symptom scores and fewer symptomatic days were seen in patients treated with BSS when compared to patients in the placebo group, but the difference was not significant due to a large overlap of confidence intervals between the two groups [49] .
Most studies report that suppression of H. pylori infection with bismuth salts correlated with symptomatic improvement [13] . This may result from the improvement in histological gastritis. One study, reported by Kang, has shown that, in parallel with the suppression of H. pylori infection, significantly more patients benefitted from bismuth (DeNol) treatment than from placebo when histological gastritis was present, whereas there was no difference between the two groups in patients without histological gastritis [50] .
It may be argued that the poor effect of treatment with a single bismuth agent results from a lower eradication rate of H. pylori infection [51] since histological gastritis, together with an increase in the number of bacteria in the stomach, recurred rapidly after discontinuation of treatment [49] . Furthermore, many early studies only followed patients up to three months [47] . This may be too short a period of follow-up to see a possible difference between patients with and without H. pylori infection after eradication treatment. Several recent studies have prolonged the observation period up to nearly three years following cure of the infection [52] [53] [54] [55] . McCarthy et al. prospectively studied the effect of eradication of H. pylori infection with colloidal bismuth subcitrate (CBS) or metronidazole plus amoxicillin or CBS plus metronidazole and amoxicillin on the symptoms of 83 H. pylori-positive NUD patients followed for one year [53] . They found that H. pylori eradication therapy significantly improved symptom scores at four weeks after treatment compared to those at entry. This was more significant in patients in whom the infection was cured [53] . At one year, the symptom scores returned almost to baseline in patients with persistent infection, whereas a significant and continued fall in the scores was seen in patients cured [53] . Furthermore, the sustained symptom improvement correlated with the higher eradication rate of the infection in those treated with the three drug combination. These results suggest a possible role of H. pylori infection in the development of dyspeptic symptoms in NUD patients, although this study suffered from several methodological problems including lack of randomization and no placebo control group. In a better designed and randomized, placebo-controlled study, eradication of H. pylori infection did not improve dyspeptic symptoms in NUD patients when compared to placebo at six weeks or six months following treatment, although both groups showed a good response to treatment at week six [56] . However, this could have been due to the shorter time of followup.
In a study from Italy, Lazzaroni et al. randomized 41 NUD patients to treatment with either four-week CBS plus one-week metronidazole or placebo and compared the histological change in the severity of gastritis and clinical improvement in symptom scores [52] . Eradication of H. pylori infection was achieved in 64 percent (16/25) of the patients treated with dual therapy and 25 percent (6/24) with CBS plus placebo. In the dual therapy group, a significant improvement in the histological gastritis at eight and 24 weeks post-therapy was seen in patients cured, but not in those with persistent infection. This also was the case in the CBS plus placebo group [52] . Eradication of H. pylori infection correlated significantly with the decrease in symptom scores in NUD patients especially at 24 weeks after treatment compared to those with the infection [52] . However, there was no association between H. pylori status and symptom subgroups (ulcer-like and dysmotility-like) in symptom scores before or after treatment [52] . A similar result was reported by Sheu et al . who compared the long-term effect of H. pylori eradication on symptom relief and gastritis in 41 young NUD patients (< 45 years) treated with CBS-based triple therapy or H2-receptor antagonist and confirmed that eradication of the infection improved in both symptom and gastritis scores [54] . Indeed, there seems to be a correlation between the suppression of H. pylori infection and an improvement in dyspeptic symptoms [22] , although contrasting reports do exist in the literature [55, 57] [58] . Ofman's study reported a similar result suggesting that initial anti-H. pylori therapy is the most cost-effective management strategy in H. pylori-seropositive patients with dyspepsia [59] .
Few studies have examined the cost-effectiveness of testing for H. pylori infection and initial empiric treatment in patients with dyspepsia. Sonnenberg found that the costbenefit relationship of serological screening for H. pylori in dyspeptic patients is influenced primarily by the response rate of nonulcer dyspepsia to H. pylori eradication and secondly by the monetary benefit of ulcer prevention in H. pylori positive patients [61] . A response to H. pylori eradication in 5 to 10 percent of all patients with dyspepsia would make screening and treatment for H. pylori a beneficial option [61] . Furthermore, potential benefits associated with H. pylori eradication may outweigh the risk of continued H. pylori exposure in some patients and may prevent progression to peptic ulcer disease, MALT lymphoma or gastric adenocarcinoma. Therefore, the decision to test for and treat H. pylori infection should be made on a case-by-case basis. Testing for H. pylori infection is only recommended if eradication treatment is planned. For patients who present with previously uninvestigated dyspepsia in whom a diagnosis of organic disease is possible, testing for H. pylori or together with other investigations to establish the clinical diagnosis should be considered. For those with alarm symptoms such as weight loss, bleeding, anemia or dysphagia, a formal diagnostic evaluation by endoscopy should be undertaken.
In conclusion, H. pylori infection and patients with dyspeptic symptoms are both widely prevalent in the general population. There is evidence to suggest that eradication of H. pylori may benefit dyspeptic patients over a long term. However, well-conducted, long-term clinical trials are needed to assess the effectiveness of such treatments, improvement of dyspeptic symptoms and cost.
